A combined effect of immune checkpoint inhibitors and a CD40 agonistic antibody in a pancreatic cancer mouse model

被引：0
|
作者：
Ichikawa, Juri [1 ]
Kawano, Kuniyuki [1 ,2 ]
Kato, Shingo [1 ,3 ]
Kurotaki, Daisuke [1 ,4 ]
Kuroishikawa, Ryo [1 ]
Kawase, Wataru [1 ,5 ]
Yoshida, Haruka [1 ]
Hiroshima, Yukihiko [5 ]
Endo, Itaru [6 ]
Maeda, Shin [2 ]
Nakajima, Atsushi [3 ]
Tamura, Tomohiko [1 ]
机构：
[1] Yokohama City Univ, Dept Immunol, Yokohama, Kanagawa, Japan
[2] Yokohama City Univ, Dept Gastroenterol, Yokohama, Kanagawa, Japan
[3] Yokohama City Univ, Dept Gastroenterol & Hepatol, Yokohama, Kanagawa, Japan
[4] Kumamoto Univ, Lab Chromatin Org Immune Cell Dev, Kumamoto, Japan
[5] Kanagawa Canc Ctr, Res Inst, Ctr Canc Genome Med, Yokohama, Kanagawa, Japan
[6] Yokohama City Univ, Dept Gastrol Surg, Yokohama, Kanagawa, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
J-2009
引用
收藏
页码：763 / 763
页数：1
相关论文
共 50 条
  • [1] Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
    David Digomann
    Max Heiduk
    Charlotte Reiche
    Jessica Glück
    Christoph Kahlert
    Peter Mirtschink
    Anna Klimova
    Florian Bösch
    Torsten Tonn
    Jochen Gaedcke
    Michael Ghadimi
    Jürgen Weitz
    Lena Seifert
    Adrian M. Seifert
    npj Precision Oncology, 7
  • [2] Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
    Digomann, David
    Heiduk, Max
    Reiche, Charlotte
    Glueck, Jessica
    Kahlert, Christoph
    Mirtschink, Peter
    Klimova, Anna
    Boesch, Florian
    Tonn, Torsten
    Gaedcke, Jochen
    Ghadimi, Michael
    Weitz, Juergen
    Seifert, Lena
    Seifert, Adrian M.
    NPJ PRECISION ONCOLOGY, 2023, 7 (01)
  • [3] Nonredundant roles for immune checkpoint blockade and agonistic CD40 in mediating T-cell responses in pancreatic ductal adenocarcinoma
    Morrison, Alexander H.
    Byrne, Katelyn T.
    Vonderheide, Robert H.
    CANCER RESEARCH, 2018, 78 (13)
  • [4] Agonistic CD40 Antibodies in Cancer Treatment
    Djureinovic, Dijana
    Wang, Meina
    Kluger, Harriet M.
    CANCERS, 2021, 13 (06) : 1 - 18
  • [5] Agonistic CD40 Antibodies and Cancer Therapy
    Vonderheide, Robert H.
    Glennie, Martin J.
    CLINICAL CANCER RESEARCH, 2013, 19 (05) : 1035 - 1043
  • [6] Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
    Richman, Lee P.
    Vonderheide, Robert H.
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (01) : 19 - 26
  • [7] Agonistic CD40 antibody therapy induces formation of tertiary lymphoid structures in glioma and inhibits the response to immune-checkpoint blockade
    van Hooren, Luuk
    Vaccaro, Alessandra
    Georganaki, Maria
    Ramachandran, Mohanraj
    Huang, Hua
    Lau, Joey
    Smits, Anja
    Essand, Magnus
    Dimberg, Anna
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [8] Multivalent Porous Silicon Nanoparticles Enhance the Immune Activation Potency of Agonistic CD40 Antibody
    Gu, Luo
    Ruff, Laura E.
    Qin, Zhengtao
    Corr, Maripat
    Hedrick, Stephen M.
    Sailor, Michael J.
    ADVANCED MATERIALS, 2012, 24 (29) : 3981 - 3987
  • [9] Agonistic antibody to CD40 blocks human lymphocyte apoptosis in an in vitro model of sepsis
    Schwulst, SJ
    Chang, K
    Osborne, D
    Ferguson, T
    Hotchkiss, R
    CRITICAL CARE MEDICINE, 2005, 33 (12) : A136 - A136
  • [10] Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer
    Fransen, Marieke F.
    Cordfunke, Robert A.
    Sluijter, Marjolein
    van Steenbergen, Mies J.
    Drijfhout, Jan W.
    Ossendorp, Ferry
    Hennink, Wim E.
    Melief, Cornelis J. M.
    VACCINE, 2014, 32 (15) : 1654 - 1660
12345